cytogenetics

The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business. 

NEW YORK (GenomeWeb) – CombiMatrix is developing two new tests that will expand its place in the reproductive health market, one of which will complement existing chromosomal microarray analysis services and the other of which will open CombiMatrix up to a new market segment.

NEW YORK (GenomeWeb News) – CombiMatrix today announced a 13 percent spike in first quarter revenues, driven by a 34 percent jump in sales generated by its prenatal chromosomal microarray analysis testing services.

NEW YORK (GenomeWeb) – PerkinElmer will continue to sell microarrays and software developed by Signature Genomics, despite its decision to shutter the company's laboratory services business.

NEW YORK (GenomeWeb) – PerkinElmer has decided to close its Signature Genomics cytogenetic testing services business.

NEW YORK (GenomeWeb) - While chromosomal microarray analysis has become the first-tier cytogenetic test for diagnosing individuals with constitutional abnormalities around the world, geneticists continue to struggle with a high level of findings of unknown significance.

Affymetrix has provided more information about how it achieved US Food and Drug Administration clearance for its CytoScan Dx Assay chromosomal microarray analysis offering.

Chromosomal microarray analysis may be widely regarded as a first-tier method for both pediatric and prenatal cytogenetic testing, but that hasn't convinced some insurers to reimburse such tests.

NEW YORK (GenomeWeb News) – Two forms of a rare subgroup of acute lymphoblastic leukemia form through chromothripsis, or catastrophic chromosome shattering, researchers from the Wellcome Trust S

The discovery of variants of unknown significance during a prenatal chromosomal microarray analysis can create headaches for genetic counselors who are used to delivering certain results to patients, according to the authors of a recent paper.

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.